洛铂联合长春瑞滨对NSCLC术后辅助化疗疗效及安全性研究

Efficacy and Safety of Lobaplatin Plus Vinorelbine in Postoperative Adjuvant,Chemotherapy for Patients with NSCLC

目的探讨非小细胞肺癌术后患者联用洛铂(LBP)与长春瑞滨(NVB)的有效性和安全性。方法对60例非小细胞肺癌患者采用长春瑞滨联合洛铂方案治疗,21天为1个治疗周期,治疗两个周期以上。结果 60例患者中53例可进行疗效评价,完全缓解、部分缓解、无变化和进展的例数分别为18例、21例、11例和2例。总治疗有效率和疾病控制率分别为37.7%和75.5%。主要不良反应为可逆性的骨髓抑制和胃肠道反应,治疗过程中未出现肝肾毒性作用。结论洛铂联合长春瑞滨作为NSCLC患者术后的辅助化疗疗效尚可,不良反应在耐受范围,可对患者生活质量提升有一定的效果。

Objective To investigate the efficacy and safety of lobaplatin（ LBP） and vinorelbine（ NVB） in postoperative adjuvant chemotherapy for patients with non-small cell lung cancer（ NSCLC）. Methods 60 patients with NSCLC were treated with vinorelbine and lobaplatin. The treatment lasted for more than 2 cycles,and 1 cycle for 21 days. Results 53 cases could receive curative effect evaluation,18 cases of complete remission,21 cases of partial remission,no change 11 cases and progress 2cases,respectively. The ORR and DCR rate were 37. 7% and 75. 5%,respectively. The main adverse reactions were myelosuppression and gastrointestinal reactions. Conclusion Lobaplatin plus vinorelbine are effective and well tolerated in postoperative adjuvant chemotherapy for patients with NSCLC,and can improve the quality of life of patients.